

Using Form-based Tagging

If **Form-based mode is enabled**, the Questions will be available for answer in the right panel (red box); the Question under review has a **light blue background**, and all Questions should either be answered or marked “Not Relevant”.

The screenshot displays the Form-based Tagging interface. On the left is a sidebar with navigation options: Nest Home, Literature Search, Screening, Tagging, Extraction, Study Inspector, and Synthesis. The main area shows a research article titled "5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study". The right-hand panel, titled "Questions (3/11)", contains a question about study conclusions, an "Annotate or Enter Text" field, and buttons for "Not Relevant" and "Apply". Below the question is a section for "Inclusion/Exclusion Criteria" with a "Select Tag" dropdown and an "Age" field. At the bottom of the right panel are expandable sections for "Tagging", "Comments (0)", and "History". A red arrow points to the "Tagging" section.

All tags can still be added to the study using Standard Tagging by expanding the Tagging panel (red arrow above).

Answering Questions

By adding Answers, you are applying the underlying tag, with the tag content serving as the evidence that the correct Answer(s) have been added. The method of Answering depends on the type of Question, but for all Question types, the tags applied will populate the [Qualitative Synthesis](#) in the same manner as Standard Tagging.

Note: Tag Recommendations are not available for Form-based Tagging mode.

Question Type-specific Answers

For each Question in the list, complete the following actions based on the type of Question:

- **Single Select:** Apply one child tag that answers the pre-configured questions. To do so, select one of the tags from the drop-down, and then highlight or select an Excerpt.

Nest Home

Dashboard
Settings

Literature Search

Other Sources
Duplicate Review
Search Exploration
Query Builder

Screening 4 / 4

Configure Screening

Tagging 0 / 4

Configure Tagging

Extraction 0 / 4

Configure Extraction

Study Inspector

Synthesis

Manuscript Editor
Abstract Editor
Export

Abstract Full Text Supplements Related Reports
PMCID: PMC6000000

cancer: a randomized Phase IIb study

This article was published in the following Dove Press journal:
Cancer Management and Research
15 June 2015
[Number of times this article has been viewed](#)

J Randolph Hecht¹
Edith P Mitchell²
Takayuki Yoshino³
Manfred Welslau⁴
Xun Lin⁵
Edna Chow Maneval⁶
Jolanda Paolini⁷
Maria Jose Lechuga⁷
Albrecht Kretzschmar⁸

¹David Geffen School of Medicine at UCLA, Santa Monica, CA;
²Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA; ³National Cancer Center Hospital East, Chiba, Japan;
⁴Onkologische Praxis Klausmann/Welslau, Aschenburg, Germany;
⁵Pfizer Oncology, La Jolla, Seragon Pharmaceuticals, San Diego, CA, USA; ⁶Pfizer Oncology, Milan, Italy;
⁷Klinikum St Georg, Leipzig, Germany

Background: Sunitinib is an oral inhibitor of tyrosine kinase receptors implicated in tumor proliferation, angiogenesis, and metastasis. In this randomized, multicenter, open-label Phase IIb study, sunitinib plus mFOLFOX6 (oxaliplatin plus leucovorin plus 5-fluorouracil) was compared with bevacizumab plus mFOLFOX6 as first-line therapy in patients with metastatic colorectal cancer.

Methods: Patients were stratified by performance status, baseline lactate dehydrogenase level, and prior adjuvant treatment, and randomized 1:1 to receive sunitinib 37.5 mg/day for 4 weeks on and 2 weeks off plus mFOLFOX6 every 2 weeks or bevacizumab 5 mg/kg every 2 weeks plus mFOLFOX6 every 2 weeks. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, overall survival, safety, and quality of life.

Results: Enrollment was closed early following accrual of 191 patients, based on an interim analysis showing an inferior trend in the primary progression-free survival efficacy endpoint for sunitinib. Ninety-six patients were randomized to sunitinib plus mFOLFOX6 and 95 to bevacizumab plus mFOLFOX6. Median progression-free survival was 9.3 months and 15.4 months, respectively, but the objective response rate was similar between the study arms. Median overall survival was 23.7 months and 34.1 months, respectively. Dose reductions and interruptions were more common with sunitinib. Hematologic toxicity was more common in the sunitinib arm.

Conclusion: While the results of the sunitinib arm are comparable with those of previously reported FOLFOLX combinations, the sunitinib-based combination was associated with more toxicity than that observed with bevacizumab and mFOLFOX6. The bevacizumab arm had an unexpectedly good outcome, and was much better than that seen in the Phase III trials.

Content Not Peer Reviewed
 Cancer Management and Research downloaded from https://www.dovepress.com/ on 14-Oct-2022
 For personal use only.

Navigation

Back Skip Complete

Questions (4/11)

Study Type: What was the study type?

RCT Prospective Observational

Enter Text

Not Relevant Relevant Apply

Study Objective: What was the study objective?

[Selection]

Tagging

Comments (0)

History

- **Multi-Select:** Any of the child tags can be an answer, so you can apply as many tags from the drop-down as are applicable to the study. When all relevant child tags are added, select “Next” to mark the Question complete.

[illegible]

- **Single Apply:** The tag under review is either applied to the study (select “Apply”) or marked irrelevant. No child tags are added!

Nest Home

Dashboard
Settings

Literature Search

Other Sources
Duplicate Review
Search Exploration
Query Builder

Screening 4 / 4

Configure Screening

Tagging 0 / 4

Configure Tagging

Extraction 0 / 4

Configure Extraction

Study Inspector

Synthesis

Manuscript Editor
Abstract Editor
Export

Abstract
Full Text
Supplements
Related Reports

Q

Cancer Management and Research downloaded from https://www.dovepress.com/ on 14-Oct-2022
for personal use only

cancer: a randomized Phase IIb study

This article was published in the following Dove Press journal:
Cancer Management and Research
15 June 2015
[Number of times this article has been viewed](#)

J Randolph Hecht¹
Edith P Mitchell²
Takayuki Yoshino³
Manfred Welslau⁴
Xun Lin⁵
Edna Chow Maneval⁶
Jolanda Paolini⁷
Maria Jose Luchaga⁷
Albrecht Kretzschmar⁸

¹David Geffen School of Medicine at UCLA, Santa Monica, CA;
²Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA; ³National Cancer Center Hospital East, Chiba, Japan; ⁴Onkologische Praxis Klausmann/Welslau, Aschaffenburg, Germany; ⁵Pfizer Oncology, La Jolla, ⁶Seragon Pharmaceuticals, San Diego, CA, USA; ⁷Pfizer Oncology, Milan, Italy; ⁸Klinikum St Georg, Leipzig, Germany

PMC

Background: Sunitinib is an oral inhibitor of tyrosine kinase receptors implicated in tumor proliferation, angiogenesis, and metastasis. In this randomized, multicenter, open-label Phase IIb study, sunitinib plus mFOLFOX6 (oxaliplatin plus leucovorin plus 5-fluorouracil) was compared with bevacizumab plus mFOLFOX6 as first-line therapy in patients with metastatic colorectal cancer.

Methods: Patients were stratified by performance status, baseline lactate dehydrogenase level, and prior adjuvant treatment, and randomized 1:1 to receive sunitinib 37.5 mg/day for 4 weeks on and 2 weeks off plus mFOLFOX6 every 2 weeks or bevacizumab 5 mg/kg every 2 weeks plus mFOLFOX6 every 2 weeks. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, overall survival, safety, and quality of life.

Results: Enrollment was closed early following accrual of 191 patients, based on an interim analysis showing an inferior trend in the primary progression-free survival efficacy endpoint for sunitinib. Ninety-six patients were randomized to sunitinib plus mFOLFOX6 and 95 to bevacizumab plus mFOLFOX6. Median progression-free survival was 9.3 months and 15.4 months, respectively, but the objective response rate was similar between the study arms. Median overall survival was 23.7 months and 34.1 months, respectively. Dose reductions and interruptions were more common with sunitinib. Hematologic toxicity was more common in the sunitinib arm.

Conclusion: While the results of the sunitinib arm are comparable with those of previously reported FOLFOX combinations, the sunitinib-based combination was associated with more toxicity than that observed with bevacizumab and mFOLFOX6. The bevacizumab arm had an unexpectedly good outcome, and was much better than that seen in the Phase III trials.

Navigation

Back Skip Complete

Questions (4/11)

Study Objective: What was the study objective?

[Selection]

Not Relevant Answered Update

Study Conclusion: What were the study conclusions?

the sunitinib-based combination was associated with more toxicity than that observed with bevacizumab and mFOLFOX6.

Not Relevant Answered Update

Inclusion/Exclusion Criteria: What were the inclusion and exclusion criteria?

Tagging

Comments (0)

History

Whenever a Question has no relevant answers, select “Not Relevant” to move to the next Question.


What Answering a Question does

When a Question is finished (Applied or, for Multi-Select, when you select “Next”), or when the Question is marked Not Relevant, the count of completed Questions at the top of the right panel will update.

When all Questions are finished, you can either add tags using the Standard method (by opening the Tagging panel), or you can move to the next study by selecting “Complete” in the upper right-hand corner.

Question Search and Answer Status

You can search for a specific tag and its associated question anytime using the search bar and dropdown. Clicking on your desired option will take you directly to that question.



Once you begin answering questions, the status of these answers will be displayed next to tags in this same dropdown.

Answer Status Key:

- No Circle = Question is unanswered

- Hollow Circle = Question assigned as “Not Relevant”
- Filled Circle = Question is answered with tag applied

In the below example, Publication Type was deemed not relevant, Number of patients using device was answered with tag applied, Objective (as well as the rest of the questions) were unanswered.

Questions (2/10)

Publication Type

Number of patients using device

Objective

Conclusion

Treatment details

Procedural success rate and statement

Level of Evidence

Report metric

Lesion location

Devices used

Conclusion: What are the study conclusions?

Annotate or Enter Text

Not Relevant

Apply

Treatment details: What are the treatment details?

Schedule	Drug Type	Administration

From:

<https://wiki.nested-knowledge.com/> - **Nested Knowledge**

Permanent link:

<https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:tagging:formanswer&rev=1688769744>

Last update: **2023/07/07 22:42**